Role of Flavones in Ovarian Cancer Prevention by Insilco Approach
Posted: 7 Feb 2020 Last revised: 15 Feb 2020
Date Written: February 4, 2020
Cancer is the outreaching disease all over the world. Each year more than millions of people who are diagnosed with dreaded disease succumb to it. Recent cases show that cancer has no barriers to socio-economic conditions. Unfortunately, Cancer therapeutics have the lowest clinical trial success rate of all major diseases. This is due to the lack of successful anti-cancer drugs. The solutions to such a critical problem are surgery, chemotherapy, or medication. But there is something wrong with these treatments which are temporary basis treatment, and they have side-effects lasting for a lifetime in some cases. So, there is a growing need for the alternate treatment of cancer. Many overlooked plants around us have solutions to major problems. The biologically active compounds of these plants and their functions are not entirely revealed. Some of the elucidated biological compounds are extracted by the literature review. We have isolated biologically active compounds from the plant. These are used as ligands on target molecules. To know more about the anti-tumor activity of the biological compounds, we performed molecular docking studies between the chosen compounds and proteins involved in ovarian cancer. As of now BRACA1 C-terminal domain complexed with BAAT peptide opted. Our molecular docking studies revealed that the selected flavone compounds have the best binding affinity, efficacy, Docking score, Ionization penalties, high energy, ligand interactions, H-bonding, and best XP glide score. These evaluations drive us to achieve a clear perspective towards the herbal drug discovery to treat ovarian cancer by defining the interactions between flavone compounds with the protein.
Keywords: Natural products, Ovarian Cancer, Insilico, Drug design
Suggested Citation: Suggested Citation